OH Pharma
Products › Growth hormone axis › Tesamorelin 20 mg
Tesamorelin 10 mg OH PharmaTesamorelin 10 mg OH Pharma – back of vial
Tesamorelin 20 mg OH PharmaTesamorelin 20 mg OH Pharma – back of vial

Swipe to see the other strengths

Growth hormone axis · File 12

Tesamorelin 20 mg

Analysis in progress

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Growth hormone, GH secretagogues and GHRH analogues.

Calculate a dose →

Description

Synthetic GHRH analogue that stimulates the pituitary's natural production of growth hormone.

Studied benefits

  • Reduced abdominal visceral fat in adults living with HIV who have lipodystrophy.
  • Improved perception of abdominal appearance in this population.
  • Reduced liver fat in trials of people living with HIV who have steatosis.
  • Stimulation of GH secretion and increase in IGF-1.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • In the phase 3 trials that led to its approval, tesamorelin reduced abdominal visceral fat compared with placebo in adults living with HIV.
⚠️ Warnings and reported side effects
  • Injection-site reactions, joint and muscle pain, swelling of the extremities.
  • Possible rise in blood sugar; hypersensitivity reactions reported.
  • Contraindicated during pregnancy, with active cancer or with pituitary disorders.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate of analysis coming soon

This product's lot is awaiting its laboratory results. The certificate will be published on this page as soon as it is received. Every new lot is sent for analysis before being published here.

Sources

  1. Health Canada approves Egrifta (2014)
  2. CATIE — Tesamorelin

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products